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Materials and Methods. Unless otherwise stated, all synthetic reactions were performed using 
oven-dried glassware and under an atmosphere of argon. Anhydrous solvents (N,N-
dimethylformamide and dichloromethane) were purchased from Sigma-Aldrich and kept under 
argon. All other chemicals and reagents for chemical reactions were purchased from commercial 
vendors (Sigma-Aldrich, Oakwood Chemical, Life Technologies) and used without further 
purification. Reactions were monitored with thin layer chromatography (EMD/Merck silica gel 
60 F254 pre-coated plates) and UV light for visualization, with an acidic mixture of 
phosphomolybdic acid, cerium ammonium molybdate, or basic aqueous KMnO4 as developing 
agents. Flash chromatography purifications were carried out using EMD/Merck silica gel 60 
(230–400 mesh). 1H and 13C NMR spectra were measured on either a Bruker Prodigy 400 (400 
MHz and 101 MHz, respectively) or a Varian Inova 500 (500 MHz and 126 MHz, respectively), 
as noted. 1H and 13C NMR chemical shifts are reported as δ in units of parts per million (ppm) 
relative to tetramethylsilane (TMS, δ = 0) and calibrated using the residual solvent peak in 
chloroform (δ 7.26, singlet and δ 77.16, respectively). Data for 1H NMR are reported as follows: 
chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad), coupling constant (Hz), and integration. High-resolution mass 
spectrometry (HRMS) was performed with either a JEOL JMS-600H High Resolution Mass 
Spectrometer with fast atom bombardment (FAB) at the California Institute of Technology Mass 
Spectrometry Facility in the Division of Chemistry and Chemical Engineering or with an Agilent 
6200 Series TOF with an Agilent G1978A Multimode source in electrospray ionization (ESI), 
atmospheric pressure chemical ionization (APCI), or mixed (MM) ionization mode at the 
Caltech Beckman Institute Center for Catalysis and Chemical Synthesis. Low-resolution mass 
spectrometry (LRMS) was performed using an Agilent 1290 UHPLC–MS in positive or negative 
mode at the Center for Catalysis and Chemical Synthesis. 
 Lysogeny broth (LB) contained 10 g casein hydrolysate, 5 g yeast extract, and 10 g NaCl per 
liter. Super optimal broth (SOB) was composed of 20 g casein hydrolysate, 5 g yeast extract, 
0.58 g NaCl, 0.19 g KCl, 10 mL 1 M MgCl2, and 10 mL 1M MgSO4 per liter. Super optimal 
broth with catabolite repression (SOC) was comprised of SOB with the addition of 0.1 mL 2 M 
glucose to 1 L of SOB medium. Hyper Broth (AthenaESTM, USA) was purchased and prepared 
according to the manufacturer’s instructions. Ampicillin sodium salt (BioPioneer, USA) and 
kanamycin sulfate (BioPioneer, USA) were used at working concentrations of 200 µg/mL and 35 
µg/mL, respectively. Phosphate-buffered saline (PBS) was purchased from Thermo Fisher 
Scientific (USA) and maintained at pH 7.4. PBST was a solution comprising PBS and 0.1% v/v 
Tween-20. Q5 Hot Start High-Fidelity DNA Polymerase, restriction endonucleases, Instant 
Sticky-End Master Mix, Antarctic phosphatase, and Blunt Ligase Master Mix were all purchased 
from New England Biolabs (USA) and used according to the manufacturer’s instructions. DNA 
constructs were sequenced by Retrogen (USA). 
Cells were made chemically competent by using the Mix & Go E. coli Transformation Kit 
(Zymo Research, USA) according to the manufacturer’s instructions. Electrocompetent cells 
were freshly prepared as follows: 8 mL of overnight cultures were washed extensively with 300 
mM sucrose on ice. The culture was then concentrated to a final volume of 60 µL cells, after 
which 20 µL cells were mixed with 50 ng plasmid DNA. Electroporation was carried out using 
the Gene Pulse XCell (BioRad, USA) according to the recommended manufacturer’s protocol. 
Cells were immediately rescued in 500 µL SOC at 37 °C for 1 h, and plated on LB agar plates 
carrying the appropriate antibiotic supplements. Plates containing colonies were always used 
within one week for further experiments. 
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The plasmid encoding N-myristoyltransferase (NMT) and methionyl aminopeptidase 
(pHV738-NMT-MetAP) was a generous gift from the Kahn laboratory (Emory University, USA). 
The plasmid confers resistance against kanamycin and contains the p15A origin of replication.1 
 
Plasmid construction in pQE80-L. The pQE80-L vector (Qiagen, USA) confers resistance to 
ampicillin and carries a 6xHis tag following the T5 promoter sequence, lac operon and ribosomal 
binding site (RBS). To remove the 6xHis tag and RBS, pQE80-L was linearized with EcoRI and 
HindIII. The gene fragment encoding the N-terminal nonapeptide sequence from eukaryotic 
calcineurin B (hCaNB) was 5’– ATG GGT AAC GAA GCG TCT TAC CCG CTG – 3’ 
(encoding the peptide sequence MGNEASYPL for NMT recognition).  The gene encoding the 
chemoreceptor Tar was amplified from genomic DH10B E. coli DNA using primers such that 
the final PCR product read EcoRI::RBS::hCaNB::BamHI::tar::SacI::6xHis::HindIII. This PCR 
product was digested with EcoRI/HindIII and ligated into pQE80-L to yield plasmid pQE80-
hCaNB-Tar-6xHis. For the remaining bacterial proteins (CheA, FtsZ, and FtsA) amplification 
was carried out using genomic DH10B E. coli DNA as the template. Primers were designed such 
that the PCR products read BamHI::gene of interest::SacI. The PCR products were digested with 
BamHI/SacI and ligated into pQE80-hCaNB-Tar-6xHis, which was also digested with 
BamHI/SacI to yield plasmids pQE80-hCaNB-CheA-6xHis, pQE80-hCaNB-FtsZ-6xHis, and 
pQE80-hCaNB-FtsA-6xHis. These plasmids were transformed via electroporation into BL21 
cells that already harbored plasmid pHV738-NMT-MetAP, generating strains SHH001–004 
(Table S3). Colonies were selected against ampicillin and kanamycin. The primers used in this 
study are summarized in Table S1. 
 
Table S1. Primers used in construction of pQE80-L-based vectors. 
Plasmid name Forward (5’ to 3’) Reverse (3’ to 5’) 
pQE80-hCaNB-Tar-6xHis ATATGAATTCGAGGAGAAA
TTAACTATGGGTAACGAAGC
GTCTTACCCGCTGGGATCCA
TGATTAACCGTATCCGC 
TATAAGCTTCTAGTGAT
GGTGATGGTGATGGAGC
TCAAATGTTTCCCAGTTT
GGATC 
pQE80-hCaNB-CheA-6xHis ATATATGGATCCGTGAGCAT
GGATATAAGCGATTTTTATC
AGACATTTTTTGATGAA 
ATATATGAGCTCGGCGG
CGGTGTTCGCCAT 
pQE80-hCaNB-FtsZ-6xHis ATATATGGATCCATGTTTGA
ACCAATGGAACTT 
ATATATGAGCTCATCAG
CTTGCTTACGCAG 
pQE80-hCaNB-FtsA-6xHis ATATATGGATCCATGATCAA
GGCGACGGAC 
ATATATGAGCTCAAACT
CTTTTCGCAGCCAACT 
 
Plasmid construction in pBAD24. The pBAD24 vector contains an arabinose-inducible 
promoter and confers resistance against ampicillin. The gene encoding the methyl aspartate 
chemoreceptor Tar was amplified from genomic DH10B E. coli DNA using primers such that 
the final PCR product read EcoRI::hCaNB::SpeI::tar::SacI::6xHis::HindIII. Both the PCR 
product and pBAD24 were digested with EcoRI/HindIII and the resulting DNA fragments were 
ligated to make pBAD24-hCaNB-Tar-6xHis. For the remaining bacterial proteins (CheA, FtsZ, 
and FtsA, also amplified from genomic DH10B E. coli DNA), primers were designed such that 
the final PCR products read SpeI::gene of interest::SacI. The PCR products were digested with 
SpeI/SacI and ligated into pBAD24-hCaNB-Tar-6xHis, which was also digested with SpeI/SacI 
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to make the plasmids pBAD24-hCaNB-CheA-6xHis, pBAD24-hCaNB-FtsZ-6xHis, and 
pBAD24-hCaNB-FtsA-6xHis. To encode the C-terminal myc epitope tag and remove the C-
terminal His tag, phosphorylated primers were used for amplification, with the pBAD24-hCaNB-
gene of interest-6xHis as the template. (The forward primers for these four constructs are the 
same and contain the sequence encoding the myc epitope tag, whereas each reverse primer 
corresponds to a unique bacterial protein.) The template was then digested with DpnI, after 
which blunt-end ligation was performed to make the plasmids pBAD24-hCaNB-Tar-cmyc, 
pBAD24-hCaNB-CheA-cmyc, pBAD24-hCaNB-FtsZ-cmyc, and pBAD24-hCaNB-FtsA-cmyc. 
These plasmids were transformed via electroporation into BL21 cells that already harbored 
plasmid pHV738-NMT-MetAP, generating strains SHH005–012 (Table S3). Colonies were 
selected against both ampicillin and kanamycin. The primers used to design these constructs are 
summarized in Table S2. 
 
Table S2. Primers used in construction of pBAD24-based vectors. 
Plasmid name Forward (5’ to 3’) Reverse (3’ to 5’) 
pBAD24-hCaNB-Tar-6xHis ATATATGAATTCACCATGG
GTAACGAAGCGTCTTACCC
GCTGACTAGTATGATTAAC
CGTATCCGC 
TATAAGCTTCTAGTGAT
GGTGATGGTGATGGAGC
TCAAATGTTTCCCAGTTT
GGATC 
pBAD24-hCaNB-CheA-6xHis ATATATACTAGTGTGAGCA
TGGATATAAGCGATTTTTA
TCAGACATTTTTTGATGAA 
ATATATGAGCTCGGCGG
CGGTGTTCGCCAT 
pBAD24-hCaNB-FtsZ-6xHis ATATATACTAGTATGTTTG
AACCAATGGAACTT 
ATATATGAGCTCATCAG
CTTGCTTACGCAG 
pBAD24-hCaNB-FtsA-6xHis ATATATACTAGTATGATCA
AGGCGACGGAC 
ATATATGAGCTCAAACT
CTTTTCGCAGCCAACT 
pBAD24-hCaNB-Tar-cmyc GAGCTCGAACAAAAACTTA
TTTCTGAAGAAGATCTGTA
GAAGCTTGGCTGTTTTGG 
AAATGTTTCCCAGTTTG
GATC 
pBAD24-hCaNB-CheA-cmyc GAGCTCGAACAAAAACTTA
TTTCTGAAGAAGATCTGTA
GAAGCTTGGCTGTTTTGG 
GGCGGCGGTGTTCGCCA
TA 
pBAD24-hCaNB-FtsZ-cmyc GAGCTCGAACAAAAACTTA
TTTCTGAAGAAGATCTGTA
GAAGCTTGGCTGTTTTGG 
ATCAGCTTGCTTACGCA
GG 
pBAD24-hCaNB-FtsA-cmyc GAGCTCGAACAAAAACTTA
TTTCTGAAGAAGATCTGTA
GAAGCTTGGCTGTTTTGG 
AAACTCTTTTCGCAGCC
AAC 
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Table S3. E. coli strains constructed in this study. 
 
Name Strain Genotype  
   
SHH001 BL21 AmpR, KanR 
pQE80-hCaNB-Tar-6xHis 
pHV738-NMT-MetAP 
 
SHH002 BL21 AmpR, KanR 
pQE80-hCaNB-CheA-6xHis 
pHV738-NMT-MetAP 
 
SHH003 BL21 AmpR, KanR 
pQE80-hCaNB-FtsZ-6xHis 
pHV738-NMT-MetAP 
 
SHH004 BL21 AmpR, KanR 
pQE80-hCaNB-FtsA-6xHis 
pHV738-NMT-MetAP 
 
SHH005 BL21 AmpR, KanR 
pBAD24-hCaNB-Tar-6xHis 
pHV738-NMT-MetAP 
 
SHH006 BL21 AmpR, KanR 
pBAD24-hCaNB-CheA-6xHis 
pHV738-NMT-MetAP 
 
SHH007 BL21 AmpR, KanR 
pBAD24-hCaNB-FtsZ-6xHis 
pHV738-NMT-MetAP 
 
SHH008 BL21 AmpR, KanR 
pBAD24-hCaNB-FtsA-6xHis 
pHV738-NMT-MetAP 
 
SHH009 BL21 AmpR, KanR 
pBAD24-hCaNB-Tar-myc 
pHV738-NMT-MetAP 
 
SHH010 BL21 AmpR, KanR 
pBAD24-hCaNB-CheA-myc 
pHV738-NMT-MetAP 
 
SHH011 BL21 AmpR, KanR 
pBAD24-hCaNB-FtsZ-myc 
pHV738-NMT-MetAP 
 
SHH012 BL21 AmpR, KanR 
pBAD24-hCaNB-FtsA-myc 
pHV738-NMT-MetAP 
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Protein sequences used in this study. The NMT recognition sequence is highlighted in blue. 
C-terminal epitope tags (either 6xHis or myc) are highlighted in red.  
 
pQE80-hCaNB-Tar-6xHis 
MGNEASYPLGSMINRIRVVTLLVMVLGVFALLQLISGSLFFSSLHHSQKSFVVSNQLREQQGELTSTWDLMLQT
RINLSRSAVRMMMDSSNQQSNAKVELLDSARKTLAQAATHYKKFKSMAPLPEMVATSRNIDEKYKNYYTALTE
LIDYLDYGNTGAYFAQPTQGMQNAMGEAFAQYALSSEKLYRDIVTDNADDYRFAQWQLAVIALVVVLILLVAWY
GIRRMLLTPLAKIIAHIREIAGGNLANTLTIDGRSEMGDLAQSVSHMQRSLTDTVTHVREGSDAIYAGTREIAAGN
TDLSSRTEQQASALEETAASMEQLTATVKQNADNARQASQLAQSASDTAQHGGKVVDGVVKTMHEIADSSKKI
ADIISVIDGIAFQTNILALNAAVEAARAGEQGRGFAVVAGEVRNLASRSAQAAKEIKALIEDSVSRVDTGSVLVES
AGETMNNIVNAVTRVTDIMGEIASASDEQSRGIDQVALAVSEMDRVTQQNASLVQESAAAAAALEEQASRLTQ
AVSAFRLAASPLTNKPQTPSRPASEQPPAQPRLRIAEQDPNWETFELHHHHHH 
 
pQE80-hCaNB-CheA-6xHis 
MGNEASYPLGSVSMDISDFYQTFFDEADELLADMEQHLLVLQPEAPDAEQLNAIFRAAHSIKGGAGTFGFSVL
QETTHLMENLLDEARRGEMQLNTDIINLFLETKDIMQEQLDAYKQSQEPDAASFDYICQALRQLALEAKGETPS
AVTRLSVVAKSEPQDEQSRSQSPRRIILSRLKAGEVDLLEEELGHLTTLTDVVKGADSLSAILPGDIAEDDITAVL
CFVIEADQITFETVEVSPKISTPPVLKLAAEQAPTGRVEREKTTRSNESTSIRVAVEKVDQLINLVGELVITQSMLA
QRSSELDPVNHGDLITSMGQLQRNARDLQESVMSIRMMPMEYVFSRYPRLVRDLAGKLGKQVELTLVGSSTE
LDKSLIERIIDPLTHLVRNSLDHGIELPEKRLAAGKNSVGNLILSAEHQGGNICIEVTDDGAGLNRERILAKAASQG
LTVSENMSDDEVAMLIFAPGFSTAEQVTDVSGRGVGMDVVKRNIQKMGGHVEIQSKQGTGTTIRILLPLTLAILD
GMSVRVADEVFILPLNAVMESLQPREADLHPLAGGERVLEVRGEYLPIVELWKVFNVAGAKTEATQGIVVILQS
GGRRYALLVDQLIGQHQVVVKNLESNYRKVPGISAATILGDGSVALIVDVSALQAINREQRMANTAAELHHHHH
H 
 
pQE80-hCaNB-FtsZ-6xHis 
MGNEASYPLGSMFEPMELTNDAVIKVIGVGGGGGNAVEHMVRERIEGVEFFAVNTDAQALRKTAVGQTIQIGS
GITKGLGAGANPEVGRNAADEDRDALRAALEGADMVFIAAGMGGGTGTGAAPVVAEVAKDLGILTVAVVTKPF
NFEGKKRMAFAEQGITELSKHVDSLITIPNDKLLKVLGRGISLLDAFGAANDVLKGAVQGIAELITRPGLMNVDFA
DVRTVMSEMGYAMMGSGVASGEDRAEEAAEMAISSPLLEDIDLSGARGVLVNITAGFDLRLDEFETVGNTIRAF
ASDNATVVIGTSLDPDMNDELRVTVVATGIGMDKRPEITLVTNKQVQQPVMDRYQQHGMAPLTQEQKPVAKV
VNDNAPQTAKEPDYLDIPAFLRKQADELHHHHHH 
 
pQE80-hCaNB-FtsA-6xHis 
MGNEASYPLGSMIKATDRKLVVGLEIGTAKVAALVGEVLPDGMVNIIGVGSCPSRGMDKGGVNDLESVVKCVQ
RAIDQAELMADCQISSVYLALSGKHISCQNEIGMVPISEEEVTQEDVENVVHTAKSVRVRDEHRVLHVIPQEYAI
DYQEGIKNPVGLSGVRMQAKVHLITCHNDMAKNIVKAVERCGLKVDQLIFAGLASSYSVLTEDERELGVCVVDI
GGGTMDIAVYTGGALRHTKVIPYAGNVVTSDIAYAFGTPPSDAEAIKVRHGCALGSIVGKDESVEVPSVGGRPP
RSLQRQTLAEVIEPRYTELLNLVNEEILQLQEKLRQQGVKHHLAAGIVLTGGAAQIEGLAACAQRVFHTQVRIGA
PLNITGLTDYAQEPYYSTAVGLLHYGKESHLNGEAEVEKRVTASVGSWIKRLNSWLRKEFELHHHHHH 
 
pBAD24-hCaNB-Tar-cmyc 
MGNEASYPLTSMINRIRVVTLLVMVLGVFALLQLISGSLFFSSLHHSQKSFVVSNQLREQQGELTSTWDLMLQT
RINLSRSAVRMMMDSSNQQSNAKVELLDSARKTLAQAATHYKKFKSMAPLPEMVATSRNIDEKYKNYYTALTE
LIDYLDYGNTGAYFAQPTQGMQNAMGEAFAQYALSSEKLYRDIVTDNADDYRFAQWQLAVIALVVVLILLVAWY
GIRRMLLTPLAKIIAHIREIAGGNLANTLTIDGRSEMGDLAQSVSHMQRSLTDTVTHVREGSDAIYAGTREIAAGN
TDLSSRTEQQASALEETAASMEQLTATVKQNADNARQASQLAQSASDTAQHGGKVVDGVVKTMHEIADSSKKI
ADIISVIDGIAFQTNILALNAAVEAARAGEQGRGFAVVAGEVRNLASRSAQAAKEIKALIEDSVSRVDTGSVLVES
AGETMNNIVNAVTRVTDIMGEIASASDEQSRGIDQVALAVSEMDRVTQQNASLVQESAAAAAALEEQASRLTQ
AVSAFRLAASPLTNKPQTPSRPASEQPPAQPRLRIAEQDPNWETFELEQKLISEEDL 
 
pBAD24-hCaNB-CheA-cmyc 
MGNEASYPLGSVSMDISDFYQTFFDEADELLADMEQHLLVLQPEAPDAEQLNAIFRAAHSIKGGAGTFGFSVL
QETTHLMENLLDEARRGEMQLNTDIINLFLETKDIMQEQLDAYKQSQEPDAASFDYICQALRQLALEAKGETPS
AVTRLSVVAKSEPQDEQSRSQSPRRIILSRLKAGEVDLLEEELGHLTTLTDVVKGADSLSAILPGDIAEDDITAVL
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CFVIEADQITFETVEVSPKISTPPVLKLAAEQAPTGRVEREKTTRSNESTSIRVAVEKVDQLINLVGELVITQSMLA
QRSSELDPVNHGDLITSMGQLQRNARDLQESVMSIRMMPMEYVFSRYPRLVRDLAGKLGKQVELTLVGSSTE
LDKSLIERIIDPLTHLVRNSLDHGIELPEKRLAAGKNSVGNLILSAEHQGGNICIEVTDDGAGLNRERILAKAASQG
LTVSENMSDDEVAMLIFAPGFSTAEQVTDVSGRGVGMDVVKRNIQKMGGHVEIQSKQGTGTTIRILLPLTLAILD
GMSVRVADEVFILPLNAVMESLQPREADLHPLAGGERVLEVRGEYLPIVELWKVFNVAGAKTEATQGIVVILQS
GGRRYALLVDQLIGQHQVVVKNLESNYRKVPGISAATILGDGSVALIVDVSALQAINREQRMANTAAELEQKLIS
EEDL 
 
pBAD24-hCaNB-FtsZ-cmyc 
MGNEASYPLGSMFEPMELTNDAVIKVIGVGGGGGNAVEHMVRERIEGVEFFAVNTDAQALRKTAVGQTIQIGS
GITKGLGAGANPEVGRNAADEDRDALRAALEGADMVFIAAGMGGGTGTGAAPVVAEVAKDLGILTVAVVTKPF
NFEGKKRMAFAEQGITELSKHVDSLITIPNDKLLKVLGRGISLLDAFGAANDVLKGAVQGIAELITRPGLMNVDFA
DVRTVMSEMGYAMMGSGVASGEDRAEEAAEMAISSPLLEDIDLSGARGVLVNITAGFDLRLDEFETVGNTIRAF
ASDNATVVIGTSLDPDMNDELRVTVVATGIGMDKRPEITLVTNKQVQQPVMDRYQQHGMAPLTQEQKPVAKV
VNDNAPQTAKEPDYLDIPAFLRKQADELEQKLISEEDL 
 
pBAD24-hCaNB-FtsA-cmyc 
MGNEASYPLGSMIKATDRKLVVGLEIGTAKVAALVGEVLPDGMVNIIGVGSCPSRGMDKGGVNDLESVVKCVQ
RAIDQAELMADCQISSVYLALSGKHISCQNEIGMVPISEEEVTQEDVENVVHTAKSVRVRDEHRVLHVIPQEYAI
DYQEGIKNPVGLSGVRMQAKVHLITCHNDMAKNIVKAVERCGLKVDQLIFAGLASSYSVLTEDERELGVCVVDI
GGGTMDIAVYTGGALRHTKVIPYAGNVVTSDIAYAFGTPPSDAEAIKVRHGCALGSIVGKDESVEVPSVGGRPP
RSLQRQTLAEVIEPRYTELLNLVNEEILQLQEKLRQQGVKHHLAAGIVLTGGAAQIEGLAACAQRVFHTQVRIGA
PLNITGLTDYAQEPYYSTAVGLLHYGKESHLNGEAEVEKRVTASVGSWIKRLNSWLRKEFELEQKLISEEDL 
 
Gel analyses. Sodium dodecyl sulfate–poly(acrylamide) gel electrophoresis (SDS–PAGE) was 
accomplished on a FB3000Q protein gel electrophoresis apparatus from Fisher Scientific (USA) 
using NuPAGE Novex 4–12% Bis-Tris protein gels (1.0 mm, 10-well) from Thermo Fisher 
(USA). Protein samples were mixed with an SDS loading buffer consisting of 0.05% w/v 
bromophenol blue, 0.1 M dithiothreitol (DTT), 10% w/v glycerol, 2% w/v sodium dodecyl 
sulfate, and 8 M urea in 50 mM Tris, pH 8.0. Samples were heated at 95 °C for 10 min to ensure 
denaturation and reduction of disulfide bonds. SeeBlue Plus 2 (Thermo Fisher, USA) was used 
as a molecular weight marker for all SDS–PAGE experiments. Total protein loading was 
visualized by using InstantBlue (Expedeon, Carlsbad, USA) as a coomassie blue stain, following 
the manufacturer’s instructions. 
 
Protein expression and labeling with ω-azido fatty acids. Individual colonies were used to 
inoculate LB medium supplemented with 200 µg/mL ampicillin and 35 µg/mL kanamycin, and 
cultures were grown overnight at 37 °C with mild agitation (250 rpm). Cultures were diluted 
1:50 in 10 mL LB medium (also supplemented with 200 µg/mL ampicillin and 35 µg/mL 
kanamycin) and grown until the optical density at 600 nm (OD600) reached 0.5. Protein 
expression was induced with either 1 mM isopropyl-β-D-1-thiogalactopyrannoside (IPTG) or 
0.2% w/v L-(+)-arabinose (for pQE80-L or pBAD24 vectors, respectively). At the time of 
induction, 500 µM of either 1 or 3 was added to the culture; growth was continued for an 
additional 4 h (37 °C, 250 rpm). Cultures were harvested, washed twice with PBS, and 
resuspended in a solution containing 1% w/v sodium dodecyl sulfate (SDS) in Tris pH 8.4. Lysis 
was accomplished by boiling cells at 90 °C for 5 min, after which the solution was cooled on ice. 
Benzonase nuclease (Sigma-Aldrich, USA) and protease inhibitor (cOmplete, EDTA-free, Roche, 
USA) were added to the lysate to degrade chromosomal DNA and to prevent protein proteolysis, 
respectively. The lysate was allowed to incubate at 37 °C for 1 h, after which the lysates were 
centrifuged at 13,000 rpm at 4 °C for 30 min. The supernatant was collected, and protein 
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quantification was performed using the bicinchoninic acid (BCA) assay kit (Thermo Fisher, 
USA). Lysates were separated into aliquots and stored at -80 °C until further use. Protein 
expression and labeling with fatty acids were performed in three independent replicate 
experiments. 
 
Cell viability with compounds 1–3. Individual colonies were used to inoculate LB medium 
supplemented with 200 µg/mL ampicillin and 35 µg/mL kanamycin, and cultures were grown 
overnight at 37 °C with mild agitation (250 rpm). Cultures were diluted to an OD600 of 0.1 in LB 
medium (also supplemented with 200 µg/mL ampicillin and 35 µg/mL kanamycin). To each 
culture was added 250 µM 1 or 3, or 20 µM fluorophore 2. Cultures were allowed to continue to 
grow in the presence of each compound, and OD600 was monitored every 10 min for 800 min 
using a Varioskan LUX microplate reader (Thermo Fisher, USA). The OD600 of cultures grown 
without the presence of 1–3 were also measured as a control. 
 
Preparation of fatty acid methyl esters (FAMEs) and mass analysis. Individual colonies 
were used to inoculate LB medium supplemented with 200 µg/mL ampicillin and 35 µg/mL 
kanamycin, and cultures were grown overnight at 37 °C with mild agitation (250 rpm). Cultures 
were diluted 1:50 in 10 mL LB medium (also supplemented with 200 µg/mL ampicillin and 35 
µg/mL kanamycin) and grown until OD600 reached 0.5. To each culture was added 250 µM 1 or 
3, or no fatty acid mimic as a control. Growth was continued (37 °C, 250 rpm) until OD600 
reached approximately 1.0. Cultures were harvested, washed twice with 0.5X PBS, and once 
with ddH2O before being lyophilized. Fatty acids were extracted and methylated in a single 
acidic methylation step.2 Briefly, freeze-dried cell pellets (approximately 8.0 mg) were 
resuspended in a 20: 1 v/v methanol: acetyl chloride solution and heated at 100 °C for 10 min. 
The solutions were allowed to cool to room temperature, after which 1 mL hexane and 1 mL 
water were added, and FAMEs were extracted twice with hexane (2 x 1 mL). The organic layers 
were combined and concentrated to a final volume of 200 µL for mass analysis. GC–MS analysis 
of FAMEs was accomplished using a ThermoFinnigan Trace GC equipped with a HP-5MS 
column (30 m x 0.250 mm x 0.25 µm), with the column effluent split between a flame ionization 
detector (FID) and ThermoFinnigan DSQ mass spectrometer. The GC oven was held at 90 °C for 
1 min, ramped at 3 °C / min to 140 °C, ramped at 3 °C / min to 250 °C, and finally ramped at 
20 °C / min to a final temperature of 310 °C. Known FAMEs present in E. coli were identified 
using the NIST MS Search 2.0 program and quantified against an internal standard (methyl 
behenate). GC traces of FAME extracts of cells not treated with fatty acids were compared with 
GC traces of FAME extracts of cells treated with fatty acids to identify new peaks. 
 
Lipid extraction from cells grown with 1 or 3 and mass analysis. Individual colonies were 
used to inoculate LB medium supplemented with 200 µg/mL ampicillin and 35 µg/mL 
kanamycin, and cultures were grown overnight at 37 °C with mild agitation (250 rpm). Cultures 
were diluted 1:50 in 10 mL LB medium (also supplemented with 200 µg/mL ampicillin and 35 
µg/mL kanamycin) and grown until OD600 reached 0.5. To each culture was added 250 µM 1 or 
3, or no fatty acid mimic as a control. Growth was continued (37 °C, 250 rpm) until OD600 
reached approximately 1.0. Cultures were harvested and washed twice with 0.5X PBS. Lipid 
extraction was performed following literature protocols.3 Briefly, cell pellets were resuspended 
in 120 µL 0.1% wt/v ammonium acetate (dissolved in ddH2O). To the solution was added 300 
µL methanol and 1 mL methyl-tert-butyl ether (MTBE). Solutions were briefly vortexed and 
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then sonicated for 1 hour at room temperature using a sonicator bath. 8 µg of internal standard 
(di17:0 phosphatidylcholine, phosphatidylethanolamine, and phosphatidylglycerol) (Avanti Polar 
Lipids, Alabaster, USA) was added at this time. Internal standards were prepared as 0.1 g/L 
solutions in methanol/dichloromethane (9:1) Lipids were extracted by addition of 260 µL of 
water, forming a biphasic solution, with lipids in the top (MTBE/methanol) layer. The 
MTBE/methanol layer was separated from the water layer and dried under a gentle stream of 
nitrogen. Dried samples were dissolved in 1 mL 9:1 methanol/dichloromethane for analysis 
using LC–MS. Fatty acids 1 and 3 were also dissolved to a final concentration of 10 µM in 9:1 
methanol/dichloromethane as standards for mass spectrometry. Samples were submitted to the 
Caltech Environmental Analysis Center of the Beckman Institute. Mass spectrometry (UPLC–
MS) analysis was accomplished using an Acquity I-Class UPLC coupled to a Xevo G2-S TOF 
mass spectrometer (Waters, USA). Lipid samples (injection volume, 5 µL) were separated on an 
Acquity UPLC CSH C18 column (2.1 µm x 100 mm, 1.7 µm, Waters, USA). UPLC–TOF–MSE 
data were collected in positive and negative mode using electrospray ionization (ESI). 
Indiscriminate fragmentation of all parent ions was performed with the capillary voltage set to 
2.0 KV, the cone voltage set to 30 V, and the acquisition range set for data collection between 
100 to 2000 m/z. MSE data consists of two channels acquired simultaneously. Extracted ion 
chromatograms were performed using m/z searches based on fragment ions with a mass window 
of 10 mDa. Lipids were identified from their fragmentation patterns in both negative and positive 
mode.  
 
Fluorescence labeling in cell lysates. To 100 µg protein in cell lysate diluted to 250 µL with 
PBS, was added iodoacetamide to a final concentration of 1 mM. Lysates were incubated at 
37 °C for 1 h in the dark. Then, 2 was added to each solution to a final concentration of 2 µM. 
Reactions were performed at room temperature for 10 min in the dark. Proteins were then 
precipitated by addition of chloroform and methanol. Pellets were resuspended in SDS loading 
buffer. Samples were boiled for 10 min at 95 °C, after which 20 µg lysate were subjected to 
SDS–PAGE. Protein gels were washed with a solution containing 10% acetic acid, 20% 
methanol, and 70% water, with mild agitation (2 x 30 min). Fluorescence labeling was visualized 
using a Typhoon Trio (GE Healthcare, USA) with excitation at 488 nm, the photomultiplier tube 
(PMT) voltage set to 400 V, and emission monitored using a 520 nm band pass filter. Protein 
bands corresponding to the fluorescently labeled protein of interest were quantified using 
ImageQuant TL (GE Healthcare, USA), and normalized against the intensity of that particular 
band in the coomassie lane. Fluorescence labeling was quantified for each biological replicate. 
Plots representing the average fluorescence intensities from independent experiments were 
prepared using IGOR Pro (Wavemetrics, Oregon, USA). 
 
Immunoblotting. Protein lysates were separated by SDS–PAGE and transferred to a 0.2 µm 
nitrocellulose membrane using an iBlot 2 gel transfer apparatus from Life Technologies (USA), 
following the manufacturer’s protocol. Membranes were blocked with 5% w/v non-fat dry milk 
in PBST at room temperature for 1 h, and washed three times with PBST before incubating with 
either 1:5000 PentaHis–Alexa Fluor 647 (Qiagen, USA), or 1:2000 c–myc Alexa Fluor 647 
conjugate (Cell Signaling Technologies, USA) at 4 °C overnight. Membranes (covered from 
light) were then washed five times with PBST at room temperature (10 min each wash). 
Fluorescence was visualized using a Typhoon Trio (GE Healthcare, USA) with excitation at 633 
nm, the photomultiplier tube (PMT) voltage set to 300 V, and emission monitored using a 670 
nm band pass filter. 
 – S9 – 
Expression, purification and mass spectrometry of Tar. An overnight culture of E. coli 
strain SHH001 bearing plasmids pQE80-hCaNB-Tar-6xHis and pHV738-NMT-MetAP was 
diluted 1:50 in 100 mL Hyper Broth supplemented with 200 µg/mL ampicillin and 35 µg/mL 
kanamycin and grown at 37 °C with mild agitation (180 rpm). When OD600 reached 
approximately 0.5, the culture was cooled on ice for 20 min, after which 500 µM of either 1 or 3 
and 0.025 mM IPTG were added to induce protein expression and to initiate N-terminal labeling. 
Cells were grown for an additional 20 h at reduced temperature and agitation speed (20 °C, 140 
rpm), harvested, and stored at -80 °C until use. Cell pellets were thawed and resuspended in a 
solution (4 mL/g cell mass) containing 50 mM NaH2PO4, 300 mM NaCl, 1 mg/mL lysozyme, pH 
8.0, and incubated on ice for 30 min. Lysis was achieved using a Q500 Sonicator (QSonica, 
USA), operating at a power of 500 watts and frequency of 20 kHz, with 5 s on and 25 s off bursts 
at 40% amplitude (1 min total for on cycle). The lysates were centrifuged at 13,000 rpm at 4 °C 
for 30 min, and the supernatant was discarded. To the insoluble fraction was added a solution (10 
mL) containing 100 mM NaH2PO4, 10 mM Tris, 8 M urea, 1% w/v n-dodecyl β-D-maltoside 
(DDM), pH 8.0, and incubated at 4 °C with mild agitation for 30 min. Lysates were centrifuged 
at 13,000 rpm at 4 °C for 30 min, after which the protein was purified from lysate using Ni–NTA 
agarose (Qiagen, USA) under denaturing conditions. Briefly, 10 mL lysate was incubated with 
250 µL Ni–NTA agarose at room temperature for 30 min and loaded onto the column. The 
column was washed with 10 column volumes of Buffer A (100 mM NaH2PO4, 10 mM Tris, 8 M 
urea, 0.2% w/v DDM, pH 8.0) and 10 column volumes of Buffer B (100 mM NaH2PO4, 10 mM 
Tris, 8 M urea, 0.2% w/v DDM, pH 6.3). The protein was eluted in 4 column volumes of Buffer 
C (100 mM NaH2PO4, 10 mM Tris, 8 M urea, 0.2% w/v DDM, pH 5.9) and 5 column volumes 
of Buffer D (100 mM NaH2PO4, 10 mM Tris, 8 M urea, 0.2% w/v DDM, pH 4.5). Fractions 
containing purified Tar were pooled and dialyzed against 25 mM Tris, 50 mM NaCl, 0.2% w/v 
DDM, pH 8.0 for 24 h. The protein was diluted in a solution of 0.2% v/v formic acid in 95% 
ddH2O and 5% acetonitrile to a final concentration of 20 µM. Protein samples were submitted 
for LC–MS analysis using an Agilent 1100 MSD equipped with a quadrupole detector (Agilent 
Technologies, USA) at the Proteome Exploration Laboratory of the Beckman Institute at Caltech. 
 
Expression, purification, and mass spectrometry of CheA. An overnight culture of E. coli 
strain SHH002 bearing plasmids pQE80-hCaNB-CheA-6xHis and pHV738-NMT-MetAP was 
diluted 1:50 in 100 mL Hyper Broth supplemented with 200 µg/mL ampicillin and 35 µg/mL 
kanamycin and grown at 37 °C with mild agitation (180 rpm). When OD600 reached 
approximately 0.5, the culture was cooled on ice for 20 min, after which 500 µM of either 1 or 3 
and 0.025 mM IPTG were added to induce protein expression and to initiate N-terminal labeling. 
Cells were grown for an additional 20 h at reduced temperature and agitation speed (20 °C, 140 
rpm), harvested, and stored at -80 °C until use. Pellets were thawed and resuspended in a 
solution (4 mL/g cell mass) containing 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 1 
mg/mL lysozyme, pH 8.0, and incubated on ice for 30 min. Lysis was achieved using a Q500 
Sonicator (QSonica, USA), operating at a power of 500 watts and frequency of 20 kHz, with 5 s 
on and 25 s off bursts at 40% amplitude (1 min total for on cycle). The lysates were centrifuged 
at 13,000 rpm at 4 °C for 30 min. Clarified lysates were loaded onto Ni–NTA columns (1 mL 
size, HP resin, GE Healthcare) using an ÄKTA purifier FPLC system (GE Healthcare, USA). 
CheA was eluted from the column using a linear gradient from 100% Buffer A’ (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0), 0% Buffer B’ (50 mM NaH2PO4, 300 mM 
NaCl, 500 mM imidazole, pH 8.0) to 100% Buffer B’ over 20 column volumes. Fractions 
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containing CheA were pooled and buffer exchanged into an anion exchange buffer (25 mM Tris, 
10 mM NaCl, pH 8.0) and loaded onto an anion exchange Q-Sepharose column (HiTrapTM Q 
HP, GE Healthcare) using an ÄKTA purifier FPLC system (GE Healthcare, USA). CheA was 
eluted from the Q-column by running a linear gradient from 10 mM NaCl to 1 M NaCl over 20 
column volumes. The protein was diluted in a solution of 0.2% v/v formic acid in 95% ddH2O 
and 5% acetonitrile to a final concentration of 20 µM. Protein samples were submitted for LC–
MS analysis using an Agilent 1100 MSD equipped with a quadrupole detector (Agilent 
Technologies, USA) at the Proteome Exploration Laboratory of the Beckman Institute at Caltech. 
 
Expression, purification, and mass spectrometry of FtsZ. An overnight culture of E. coli 
strain SHH003 bearing plasmids pQE80-hCaNB-FtsZ-6xHis and pHV738-NMT-MetAP was 
diluted 1:50 in 10 mL LB medium supplemented with 200 µg/mL ampicillin and 35 µg/mL 
kanamycin and grown at 37 °C with mild agitation (250 rpm). When OD600 reached 
approximately 0.5, 500 µM of either 1 or 3 and 1 mM IPTG were added to the culture to induce 
protein expression and to initiate N-terminal labeling. Cells were grown for an additional 4 h 
(37 °C, 250 rpm) and harvested. Cell pellets were resuspended in a solution containing 50 mM 
NaH2PO4, 300 mM NaCl, 5 mM imidazole, 1 mg/mL lysozyme, and incubated on ice for 30 min. 
Lysis was achieved using a Q500 Sonicator (QSonica, USA), operating at a power of 500 watts 
and frequency of 20 kHz, with 5 s on and 25 s off bursts at 30% amplitude (1 min total for on 
cycle). The lysates were centrifuged at 13,000 rpm at 4 °C for 30 min, after which the protein 
was purified from lysate using Ni–NTA agarose spin columns (Qiagen, USA) according to the 
manufacturer’s instructions. The purified protein was eluted in a buffer solution containing 50 
mM NaH2PO4, 300 mM NaCl, and 500 mM imidazole. The purified protein was further 
concentrated using 30 kDa MWCO spin filters (Millipore, USA) and the buffer was exchanged 
into a solution containing 50 mM NH4HCO3. The protein was diluted in a solution of 0.2% v/v 
formic acid in 95% ddH2O and 5% acetonitrile to a final concentration of 20 µM. ESI–TOF mass 
spectrometry was performed using an LCT Premier XE mass spectrometer (Waters, USA) at the 
Mass Spectrometry Facility in the Division of Chemistry and Chemical Engineering at Caltech. 
Mass spectra were deconvoluted using MassLynx V 4.1 (Waters, USA) and spectra were plotted 
using IGOR Pro (Wavemetrics, Oregon, USA). 
 
Expression, purification, and mass spectrometry of FtsA. An overnight culture of E. coli 
strain SHH004 bearing plasmids pQE80-hCaNB-FtsA-6xHis and pHV738-NMT-MetAP was 
diluted 1:50 in 100 mL Hyper Broth supplemented with 200 µg/mL ampicillin and 35 µg/mL 
kanamycin and grown at 37 °C with mild agitation (180 rpm). When OD600 reached 
approximately 0.5, the culture was cooled on ice for 20 min, after which 500 µM of either 1 or 3 
and 0.025 mM IPTG were added to induce protein expression and to initiate N-terminal labeling. 
Cells were grown for an additional 20 h at reduced temperature and agitation speed (20 °C, 140 
rpm), harvested, and stored at -80 °C until use. Cell pellets were resuspended in a solution (4 
mL/g cell mass) containing 100 mM NaH2PO4, 10 mM Tris, 8 M urea, pH 8.0, and were lysed at 
4 °C with mild agitation for 60 min. Lysates were clarified with centrifugation (13,000 rpm, 4 °C, 
30 min). Clarified lysate was incubated with 250 µL Ni–NTA agarose (Qiagen, USA) at room 
temperature for 30 min before being loaded onto the column. The column was washed with 10 
column volumes of 100 mM NaH2PO4, 10 mM Tris, 8 M urea, pH 8.0 and 15 column volumes of 
100 mM NaH2PO4, 10 mM Tris, 8 M urea, pH 6.3. FtsA was eluted from the column with 5 
column volumes of 100 mM NaH2PO4, 10 mM Tris, 8 M urea, pH 5.9, and 5 column volumes of 
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100 mM NaH2PO4, 10 mM Tris, 8 M urea, pH 4.5. Fractions containing FtsA were pooled and 
dialyzed against 25 mM Tris, 50 mM NaCl, pH 8.0 overnight. The protein was diluted in a 
solution of 0.2% v/v formic acid in 95% ddH2O and 5% acetonitrile to a final concentration of 20 
µM. Protein samples were submitted for LC–MS analysis using an Agilent 1100 MSD equipped 
with a quadrupole detector (Agilent Technologies, USA) at the Proteome Exploration Laboratory 
of the Beckman Institute at Caltech. 
 
Mass calibration for the Agilent 1100 MSD was performed with an internal standard of 
myoglobin in positive mode. Mass calibration for the LCT Premier XE mass spectrometer was 
performed with an internal standard consisting of sodium iodide clusters. 
 
Calculated and observed masses are summarized in Tables S4–S7. Protein masses were 
calculated using http://www.expasy.org. Masses for proteins modified with 1 or 3 take into 
account for the following: the loss of the starting Met, the addition of the fatty acid, and the loss 
of a water molecule due to amide bond formation between the fatty acid and the Gly residue. In 
cells that were not labeled with fatty acids, we observed that proteins of interest were labeled 
with endogenous myristic acid.4 Additionally, we observed the mass addition of a phosphoryl 
group on unmodified CheA. CheA has been reported to be autophosphorylated in bacterial cells.5 
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Table S4. Calculated and observed masses for modification of Tar. 
Calculated mass (Da) Observed mass 
(Da) 
+/- (Da) Notes 
    
61984.8 61984.9 4.5 Unmodified Tar (–Met) 
62208.0 Not observed  Tar modified with 1  
62229.8 62226.9 4.1 Tar modified with 1 (sodium adduct) 
62210.0 62210.2 4.6 Tar modified with 3 
Table S5. Calculated and observed masses for modification of CheA. 
Calculated mass (Da) Observed mass 
(Da) 
+/- (Da) Notes 
    
73391.5 73391.2 5.2 Unmodified CheA (–Met) 
73470.5 73471.8 
 
4.6 CheA modified by phosphorylation 
73614.7 
73636.7 
Not observed 
73635.9 
 
5.1 
CheA modified with 1  
CheA modified with 1 (sodium adduct) 
73616.7 
73638.7 
Not observed 
73638.7 
4.9 
5.1 
CheA modified with 3 
CheA modified with 3 (sodium adduct) 
    
Table S6. Calculated and observed masses for modification of FtsZ. 
Calculated mass (Da) Observed 
mass (Da) 
+/- (Da) Notes 
    
42365.1 42364.8 1.1 Unmodified FtsZ (–Met) 
42575.5 42575.1 
 
1.0 FtsZ modified with endogenous myristic acid 
42588.3 42588.2 1.0 FtsZ modified with 1  
42562.3 42562.2 
 
1.0 FtsZ modified with 1 (reduction of azide to amine) 
42590.3 42590.1 1.2 FtsZ modified with 3 
    
Table S7. Calculated and observed masses for modification of FtsA. 
Calculated mass (Da) Observed mass 
(Da) 
+/- (Da) Notes 
    
47371.1 Not observed  Unmodified FtsA (–Met) 
47581.5 47582.6 
 
3.1 FtsA modified with endogenous myristic acid 
47594.3 47594.6 3.5 FtsA modified with 1  
 
47596.3 47595.8 2.4 FtsA modified with 3 
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Labeling bacterial proteins with ω-azido fatty acids in fixed cells. Overnight cultures were 
diluted 1:50 in LB medium supplemented with 200 µg/mL ampicillin and 35 µg/mL kanamycin 
and grown at 37°C with mild agitation (250 rpm). Cells (harboring pBAD24-derived and 
pHV738-NMT-MetAP plasmids) expressing Tar or CheA were grown to an OD600 of 0.5, and 
cells expressing FtsZ and FtsA were grown to an OD600 of 0.9, after which 0.2% w/v arabinose 
and 250 µM 1 were added to the cultures. Cells were allowed to grow for an additional 2 h, after 
which aliquots of cells were concentrated to an OD600 of approximately 2. Cells were fixed by 
addition of 4% paraformaldehyde in PBS for 10 min at room temperature, and permeabilized 
with 0.3% v/v Triton X-100 for 15 min at room temperature. Proteins were alkylated by addition 
of 100 mM iodoacetamide at room temperature for 1 h in the dark. N-terminal fluorescence 
labeling was carried out by incubating the cells with 20 µM 2 at room temperature for 30 min. 
Cells were rinsed four times with PBS and blocked with 3% w/v BSA in PBS at room 
temperature for 1 h, after which c-myc Alexa Fluor 647 antibody (Cell Signaling Technologies, 
USA) was added to the solution at a 1:100 dilution. Cells were allowed to incubate with the 
antibody solution overnight at 4 °C, and washed five times with PBS the following day. Cells 
were then mounted on 5% w/v agarose (in PBS) slides for imaging. 
 
Labeling bacterial proteins with ω-azido fatty acids in live cells. Overnight cultures 
(harboring modified pBAD24 and pH738-NMT-MetAP plasmids) were diluted 1:50 in LB 
medium supplemented with 200 µg/mL ampicillin and 35 µg/mL kanamycin and grown at 37°C 
with mild agitation (250 rpm). Cells expressing Tar or CheA were grown to an OD600 of 0.5, and 
cells expressing FtsZ and FtsA were grown to an OD600 of 0.9, after which 0.2% w/v arabinose 
and 250 µM 1 or 3 were added to the cultures. Cells were allowed to grow for an additional 2 h, 
after which aliquots of cells were concentrated to an OD600 of approximately 2. Cells were rinsed 
three times with PBS, after which 2 was added to a 100 µL aliquot of cell suspension to a final 
concentration of 20 µM. The cells were incubated with 2 at 37°C for 30 min, after which the 
solution was washed three times with PBS to remove excess fluorophore. Cells were then 
mounted onto a 5% w/v agarose slide in PBS for imaging. 
 
Fluorescence microscopy. Protein localization in cells was detected using an inverted Zeiss 
LSM 5 Exciter laser scanning confocal microscope at the Biological Imaging Facility of the 
Beckman Institute at Caltech. A 488 nm laser line (25 mW argon laser, 1–2 %) and 505–550 nm 
band pass filter were used in the detection of proteins labeled by 2. Excitation at 633 nm (5 mW 
neon laser, 1–5 %) and emission at 650 nm (long pass) were used for immunofluorescence 
detection. Images were taken as 15 Z-stacks, with 0.2 µm per stack. ImageJ (NIH) was used to 
sum each Z-stack to form the projections represented in the figures. Cell Profiler was used to 
quantify the integrated fluorescence per cell for approximately 100–150 cells per sample.6 
 
Discussion on fatty acid probes 1 and 3. Gordon and coworkers previously showed that 
heteroatom-containing myristic acid analogues are well-tolerated by NMT, and that replacement 
of a methylene group by an ether oxygen atom is roughly equivalent to deletion of four 
methylene groups in terms of reduction in the hydrophobic character of the acid (Ref. 7). 
Estimated logP values for 1 and 3 were calculated using Molinspiration Chemoinformatics 
(www.molinspiration.com), resulting in logP values of 4.84 and 2.86, respectively. The software 
uses group contribution values to determine estimated partition coefficients. For a discussion on 
group contributions, see Ref. 8.  
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Discussion on fatty acid pool and intact lipids in E. coli. We analyzed the free fatty acid pool 
of bacterial cells that were treated with the azide-containing fatty acids (Fig. S9) by GC–MS. 
Cells treated with 1 showed a peak in the GC trace that matched that of the methyl ester of 1; 
otherwise, the GC trace was identical to that of untreated cells. We looked at the intact 
phospholipids by LC–MS (Fig. S10–12). In cells treated with 1, we observed a single new peak 
that was not present in untreated cells. On the basis of extracted ions in negative mode, we 
conclude that the phospholipid contained palmitic acid and 1. Fragmentation in positive mode 
showed a m/z loss of 141 Da, corresponding to a phosphorylethanolamine molecule. This would 
suggest that E. coli incorporates 1 into a PE molecule. Treatment of cells with 3 did not 
significantly alter the intact lipid profile (Fig. S26). 
 
Synthetic procedures 
 
12-azidododecanoic acid (1). To a flamed-dried 100 mL 
round bottom flask, was added 20 mL DMF, 419.1 mg 
sodium azide (6.45 mmol, 1.80 equiv), and 53.7 mg 
sodium iodide (0.36 mmol, 0.1 equiv). The mixture was stirred to form a heterogeneous 
suspension, after which 12-bromododecanoic acid (1.0 g, 3.58 mmol, 1.0 equiv) was added. The 
reaction mixture was allowed to stir at room temperature for 24 h, after which 20 mL ethyl 
acetate was added, and the solution was cooled on ice. To the resultant solution, 1 M HCl was 
added dropwise until the suspension became clear. The reaction mixture was extracted twice 
with ethyl acetate (2 x 20 mL). The organic layer was washed three times with saturated LiCl (3 
x 20 mL), dried over MgSO4, and concentrated in vacuo, resulting in a slightly yellow solid. The 
crude product was washed extensively with ice-cold ether and ice-cold water before being 
filtered. The white solid was collected and dried overnight under high vacuum to afford 785.6 
mg of 1 as a brilliant, white solid (91%). (400 MHz, CDCl3): δ 3.25 (t, 2H, J = 6.8 Hz), 2.35 (t, 
2H, J = 7.6 Hz), 1.58 – 1.65 (m, 4H), 1.30 – 1.36 (m, 6H), 1.25 – 1.30 (m, 8H). 13C NMR (101 
MHz, CDCl3): δ 179.67, 77.36, 51.63, 34.08, 29.58, 29.50, 29.35, 29.28, 29.17, 28.98, 26.85, 
24.80. HRMS (FAB) calculated for C12H24N3O2 ([M+H]+) 242.1868, found 242.1853. 
 
BCN–BODIPY conjugate (2). An oven-dried 20 mL 
scintillation vial was charged with 4,4-difluoro-5,7-
dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid 
(5 mg, 17 µmol, 1.0 equiv), O-(6-chlorobenzotriazol-1-
yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
(HCTU) (7 mg, 17 µmol, 1.0 equiv), and N-(1R,8S,9s)-
bicyclo[6.1.0]non-4-yn-9-ylmethyloxycarbonyl]-1,8-
diamino-3,6-dioxaoctane (10 mg, 31 µmol, 1.8 equiv). 
N,N-dimethylformamide (2 mL) was then added to the vial. To the solution, N,N-
diisopropylethylamine (DIPEA) (6.7 µL, 39 µmol, 2.3 equiv) was added, and the reaction 
mixture was allowed to stir at room temperature for 4 h, after which the solvent was removed in 
vacuo. The residue was taken up in 10 mL ethyl acetate and extracted twice with 1 M HCl (2 x 
20 mL), washed once with deionized water (10 mL), and washed three times with saturated LiCl 
(3 x 30 mL). The organic layer was dried over Na2SO4 and concentrated under reduced pressure 
to give a lustrous brown oil as the crude product. Flash chromatography (1–2% methanol in 
dichloromethane) afforded 9.2 mg of 2 as a brilliant, red solid (90%). 1H NMR (400 MHz, 
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CDCl3): δ, 7.08 (s, 1H), 6.89 (d, 1H, J = 4.0 Hz), 6.30 (d, 1H, J = 4.0 Hz), 6.12 (br s, 1H), 5.22 
(br s, 1H), 4.14 (br s, 1H), 4.12 (br s, 1H), 3.57 (br s, 1H), 3.54 – 3.50 (m, 4H), 3.46 – 3.42 (m, 
2H), 3.37 – 3.33 (m, 2H), 3.30 – 3.25 (m, 2H), 2.63 (t, 2H, J = 8.0 Hz), 2.56 (s, 3H), 2.25 (s, 3H), 
2.23 – 2.21 (m, 2H), 1.61 – 1.50 (m, 7H), 1.33 (t, 2H, J = 8.8 Hz), 0.91 (t, 2H, J = 9.6 Hz). 13C 
NMR (101 MHz, CDCl3): δ, 171.89, 160.27, 157.71, 156.90, 143.92, 135.20, 133.49, 128.37, 
123.88, 120.52, 117.63, 98.96, 70.39, 70.33, 70.24, 70.04, 62.90, 40.88, 39.39, 36.11, 29.16, 
24.99, 21.57, 20.22, 17.90, 15.09, 11.48. HRMS (FAB) calculated for C31H42O5N4BF2 ([M+H]+) 
599.3216, found 599.3219. 
 
6-azidohexan-1-ol (S1). To a flamed-dried 100 mL round bottom 
flask was added sodium azide (968.9 mg, 14.9 mmol, 1.8 equiv), 
sodium iodide (123.4 mg, 0.83 mmol, 0.1 equiv), and 10 mL 
DMF to form a heterogeneous suspension. To this mixture was added 6-bromohexan-1-ol (1.5 g, 
8.28 mmol, 1.0 equiv) dropwise over the course of 2 min. The reaction mixture was allowed to 
stir at room temperature for 18 h, after which the solution was diluted with 30 mL ethyl acetate 
and cooled on ice. To the solution, 10 mL 1 M HCl was slowly added to quench the reaction. 
The solution was extracted twice with 1 M HCl (2 x 10 mL), twice with deionized water (2 x 10 
mL), twice with saturated LiCl (2 x 10 mL), dried over MgSO4, and concentrated in vacuo. Flash 
chromatography (10% ethyl acetate: 90% hexanes) afforded 1.07 g of S1 as a colorless oil (90%). 
1H NMR (500 MHz, CDCl3): δ, 3.66 (t, 2H, J = 6.5 Hz), 3.28 (t, 2H, J = 7.0 Hz), 1.61 (m, 4H), 
1.41 (m, 4H). 13C NMR (126 MHz, CDCl3): δ, 62.93, 51.51, 32.69, 28.95, 26.66, 25.47. LRMS 
(ESI) calculated for C6H14N3O ([M+H]+) 144, found 144. 
 
tert-butyl 5-((6-azidohexyl)oxyl)pentanoate (S2). A 
flame-dried 50 mL flask was charged with S1 (276 mg, 
1.93 mmol, 1.1 equiv), followed by anhydrous DMF 
(10 mL), and cooled to 0°C on ice. To the solution was slowly added NaH (84.1 mg 60% wt 
dispersion in mineral oil, 2.10 mmol, 1.2 equiv), and the resulting suspension was allowed to stir 
on ice for 0.5 h. The solution was warmed to room temperature and allowed to stir for an 
additional 0.5 h, after which the reaction mixture was cooled on ice. To the reaction mixture was 
added tert-butyl 5-bromopentanoate (415.5 mg, 1.75 mmol, 1.0 equiv) dropwise over the course 
of 10 min. The reaction mixture was allowed to warm to room temperature and stirred for an 
additional 5 h, after which the solution was cooled on ice and quenched by addition of aqueous, 
saturated LiCl (20 mL). The solution was extracted twice with ethyl acetate, dried over MgSO4, 
and concentrated in vacuo. The residue was suspended in dichloromethane and purified by flash 
chromatography (1–5% ethyl acetate in hexanes) to afford 146.7 mg of S2 as a colorless oil 
(28%). 1H NMR (500 MHz, CDCl3): δ, 3.40 (t, 2H, J = 6.0 Hz), 3.39 (t, 2H, J = 6.5 Hz), 2.23 (t, 
2H, J = 7.0 Hz), 1.62 (m, 4H), 1.59 (m, 4H), 1.43 (s, 9H), 1.38 (m, 4H). 13C NMR (126 MHz, 
CDCl3): δ, 173.15, 80.16, 70.83, 70.58 51.53, 35.44, 29.74, 29.27, 28.94, 28.25, 26.71, 25.93, 
21.99. HRMS (FAB) calculated for C15H30N3O3 ([M+H]+) 300.2287, found 300.2283. 
 
5-((6-azidohexyl)oxy)pentanoic acid (3). A 20 mL 
scintillation vial was charged with S2 (140 mg, 0.47 
mmol, 1 equiv) and 2 mL dichloromethane. The reaction 
mixture was allowed to stir to form a homogenous solution, after which 2 mL trifluoroacetic acid 
was added dropwise over the course of 5 min. The reaction mixture continued to stir at room 
O
O
O
N3
O
O
OH
N3
OH
N3
 – S16 – 
temperature for 1 h, after which the trifluoroacetic acid was evaporated using a gentle stream of 
nitrogen. Remaining trifluoroacetic acid was removed by azeotropic evaporation with toluene (5 
x 5 mL) under reduced pressure to afford 3 as a faint yellow oil (quantitative). The material was 
used without further purification. 1H NMR (500 MHz, CDCl3): δ, 3.43 (t, 2H, J = 6.0 Hz), 3.40 (t, 
2H, J = 6.0 Hz), 3.26 (t, 2H, J = 7.0 Hz), 2.39 (t, 2H, J = 7.0 Hz), 1.72 (m, 2H), 1.61 (m, 6H), 
1.38 (m, 4H). 13C NMR (126 MHz, CDCl3): δ, 179.08, 70.92, 70.46, 51.53, 33.81, 29.68, 29.09, 
28.93, 26.70, 25.92, 21.72. HRMS (MM) calculated for C11H20N3O3 ([M-H]–) 242.1510, found 
242.1507. 
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Supplementary Figures 
 
 
 
Figure S1. Schematic of vector construction in pQE80-L and pHV738-NMT-MetAP 
plasmids. (A) The gene encoding the protein of interest is placed under control of the 
bacteriophage T5 promoter in the pQE80-L vector. The protein is outfitted with the N-terminal 
nonapeptide sequence from calcineurin B (hCaNB) for NMT recognition and a C-terminal 
hexahistidine tag for purification. RBS = ribosome binding site (B) Simplified vector schematic 
for pHV738-NMT-MetAP (from Ref. 1). Expression of NMT is placed under control of the Ptac 
promoter whereas methionyl aminopeptidase (MetAP) expression is placed under control of its 
own promoter. The plasmid harboring the genes encoding NMT and MetAP contains a p15A 
origin of replication. 
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Figure S2. Fluorescence emission from labeled proteins expressed from pQE80-L 
plasmids. Crude lysates from cells (labeled with 1) expressing NMT and one of the four bacterial 
proteins (Tar, CheA, FtsZ, or FtsA) from pQE80-L plasmids were treated with 2 and separated using 
SDS–PAGE. Fluorescence measurements (from gels corresponding to Figure 2) were normalized to 
the band corresponding to the labeled protein in the coomassie lane. Error bars denote standard 
deviations from three independent experiments. Shown below the bar graphs are the fluorescence 
and coomassie gels in inverted grayscale. The regions boxed in yellow denote the band regions 
which were used in quantifying fluorescence emission. Fluorescence emission was normalized 
against the intensity from the associated coomassie gels. 
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Figure S3. Deconvoluted mass spectra of Tar. (A) Tar isolated from cells expressing both 
NMT and Tar but not labeled with 1. The mass at 61984 Da corresponds to unmodified Tar. (B) 
Tar isolated from cells labeled with 1. The mass at 62227 Da corresponds to Tar modified with 1 
(sodium adduct). Calculated and observed masses for modification of Tar are listed in Table S4. 
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Figure S4. Deconvoluted mass spectra of CheA. (A) CheA isolated from cells expressing 
both NMT and CheA but not labeled with 1. The mass at 73472 Da corresponds to the 
phosphorylated form of CheA. (B) CheA isolated from cells labeled with 1. The mass at 73636 
Da corresponds to CheA modified with 1 (sodium adduct). Calculated and observed masses for 
modification of CheA are listed in Table S5.   
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Figure S5. Deconvoluted mass spectra of FtsZ. (A) FtsZ isolated from cells expressing both 
NMT and FtsZ but not labeled with 1. The mass at 42365 Da corresponds to unmodified FtsZ, 
and the mass at 42575 Da corresponds to FtsZ modified from endogenous myristic acid. (B) 
FtsZ isolated from cells labeled with 1. The mass at 42588 Da corresponds to FtsZ modified 
with 1. The mass at 42562 Da corresponds to FtsZ modified with 1, with reduction of the 
terminal azide to an amine. Calculated and observed masses for modification of FtsZ are listed 
in Table S6. 
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Figure S6. Deconvoluted mass spectra of FtsA. (A) FtsA isolated from cells expressing both 
NMT and FtsA but not labeled with 1. The mass at 47583 Da corresponds to FtsA modified from 
endogenous myristic acid. (B) FtsA isolated from cells labeled with 1. The mass at 47595 Da 
corresponds to FtsA modified with 1. Calculated and observed masses for modification of FtsA 
are listed in Table S7. 
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Figure S7. Screening fatty acid and fluorophore concentration ranges. Cells not 
expressing a target protein were grown at 37 °C to OD600 = 0.5 and treated as described in (A) – 
(C). After treatment, cells were washed three times with PBS and imaged by confocal 
fluorescence microscopy. (A) Cells that were not treated with 1 were labeled with different 
concentrations of 2 for 30 min at 37 °C. Scale bar = 10 µm. (B) Cells that were treated for 2 h 
with different concentrations of 1 were labeled with 20 µM 2. Scale bar = 10 µm. (C) Cells that 
were treated for 2 h with 250 µM 1 and labeled for 30 min with different concentrations of 2. 
Fluorescence can be observed for 10 µM 2 and low fluorescence is observed for 1 µM 2. Scale 
bar = 2 µm. 
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Figure S8. Addition of 1, 2, or 3 does not affect cell growth. Cells were diluted from an 
overnight culture to an OD600 = 0.1. Cells were then treated with either 1, 2, or 3, and continued 
to grow through the course of 800 min. OD600 was monitored every 10 min for each culture. E. 
coli strain SHH010 (culture bearing plasmids pBAD24-hCaNB-CheA-myc and pHV738-NMT-
MetAP) was used in this experiment. 
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Figure S9. GC traces of fatty acid methyl esters (FAMEs) extracted from E. coli. FAMEs 
were extracted from cells that were (A) untreated with fatty acids, (B) treated with 1, or (C) 
treated with 3. The methyl ester derivative of 1 is found in (B) at t = 37.84 min. (D) Zoomed 
image comparing FAMEs from untreated cells (top) and cells treated with 1 (bottom). For cells 
treated with 3, the fatty acid pool is essentially identical to that of cells that were not treated with 
any azido-fatty acids. (E) Compound 1 was subjected to esterification and injected for GC–MS 
analysis. The elution time (t = 37.75 min) matches that of the peak in trace (B) at t = 37.84 min. 
The methyl ester of endogenous myristic acid (C14:0) is labeled in traces A–C. FAME analysis 
yields no evidence that probes 1 and 3 undergo chain-length redistribution. 
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Figure S10. LC traces of intact lipids from E. coli. Intact lipids were extracted from cells (A) 
untreated with azide-containing fatty acids or (B) treated with 1. (B) Fatty acid probe 1 is 
incorporated into a phosphatidylethanolamine with a C16 acyl chain (t = 3.48 min). Identification 
of PE molecule eluting at t = 3.48 min was performed by analysis of fragmentation patterns in 
both negative (Figure S11) and positive (Figure S12) mode. BPI = Base peak intensity. 
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Figure S11. Identification of fatty acids from phospholipids (negative mode). (A) Base peak 
ion (BPI) chromatogram of cells treated with 1. (B) Extracted ion chromatogram (EIC) for 
phospholipid (parent ion), using m/z value search from MS1 channel (m/z = 675.422 – 675.484 ± 
0.010 Da). Elution peak occurs at t = 3.48 min. (C and D) Identification of individual chain 
components of phospholipid eluting at t = 3.48 min. EICs were generated using m/z values from 
MS2 channel (fragment ions). (C) EIC for m/z value corresponding to 1 (m/z = 240.171 ± 0.010 Da). 
(D) EIC for m/z value corresponding to palmitic acid (m/z = 255.233 ± 0.010 Da). The fragment ions 
(traces C and D) show an elution peak at t = 3.48 min, matching that of the peak corresponding to 
the parent ion (trace B) and indicating that 1 is incorporated into a cellular lipid bearing a palmitic 
acid chain. Max ion count for traces A–D: 2.24 x 106. (E) Probe 1 was run to confirm production of 
the expected ion at the expected m/z. 
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Figure S12. Identification of fatty acids from phospholipids (positive mode). (A) Base peak 
ion (BPI) chromatogram of cells treated with 1. (B) Extracted ion chromatogram (EIC) for 
phospholipid (parent ion), using m/z value search from MS1 channel (m/z = 677.234 – 677.304 ± 
0.010 Da). (C) EIC for the fragment ion (MS2 channel; m/z = 536.292 ± 0.010 Da) shows an elution 
peak at t = 3.48 min. The difference in m/z between the parent ion in (B) and fragment ion in (C) 
suggests the loss of phosphorylethanolamine (calculated m/z: 141.019 Da), consistent with 
formation of a phosphatidylethanolamine bearing acyl chains derived from 1 and palmitic acid. Max 
ion count for traces A–C: 2.58 x 106. 
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Figure S13. In-gel fluorescence detection of proteins expressed from pBAD24 plasmids 
and labeled with 1. (A) The gene encoding the protein of interest is placed under control of the 
PBAD promoter in the modified pBAD24 plasmid. The protein is outfitted with the N-terminal 
nonapeptide sequence from calcineurin B (hCaNB) for NMT recognition and a C-terminal myc-
tag (cmyc) for immunoblotting and immunofluorescence imaging. RBS = ribosome binding site. 
(B) In-gel fluorescence analysis shows NMT can achieve site-specific labeling of E. coli proteins 
expressed under control of the arabinose-inducible promoter. SDS–PAGE analysis of E. coli 
lysates. Protein expression was achieved by addition of 0.2% w/v L-arabinose (Ara). Cultures 
were labeled with 1 when protein expression was induced. Cells were lysed and lysates were 
treated with 2. Western blot analysis against a C-terminal myc tag with a primary antibody 
conjugated to Alexa Fluor 647 confirms protein expression.  
 
The T5 promoter can exhibit basal expression in the absence of an inducer. The pBAD 
promoter is more tightly regulated with reduced basal expression. In cells outfitted with pBAD24 
plasmids, NMT is constitutively expressed under control of the tac promoter. We found sufficient 
labeling for imaging with basal NMT expression. For a comparison of expression systems, see 
Ref. 9. 
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Figure S14. Immunofluorescence labeling of bacterial proteins. Bacterial proteins that are 
not labeled with 1 show localization patterns indistinguishable from those treated with 1. Polar 
localization is observed for Tar and CheA; septal localization for FtsZ and FtsA. After protein 
expression was induced, cells were fixed, permeabilized, and treated with 2 and an anti–myc 
antibody conjugated to Alexa Fluor 647. (scale bar = 2 µm). 
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Figure S15. Immunofluorescence labeling of uninduced cells or uninduced cells treated 
with 1. Control experiments where cells do not express a target protein but are treated with 1, 2, 
and antibody (following fixation and permeabilization) show no observable, distinct localization 
patterns (for all four proteins Tar, CheA, FtsZ, and FtsA), confirming that there is little 
interference from labeling of free 1 or of 1 incorporated into membrane lipids (scale bar = 1 µm). 
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Figure S16. Relative fluorescence intensities for live cells labeled with 1 or 3 and 2. 
Fluorescence signal from cells was quantified using Cell Profiler. Background signal was 
measured from cells that were not expressing protein targets but were treated with 250 µM of 
either (A) 1 or (B) 3, and labeled with 20 µM 2. The fold changes above background for Tar, 
CheA, FtsZ, and FtsA are (A) 2.7, 9.8, 10.8, and 7.1 and (B) 2.5, 8.4, 8.8, and 4.8, respectively. 
Error bars denote standard deviation from fluorescence quantification for 100–150 cells for each 
of the cells expressing one of the four protein targets or cells used for quantifying background 
signal. 
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Figure S17. Cells can be labeled with lower concentrations of arabinose. We were able to 
achieve similar labeling when protein targets were induced with lower concentrations of 
arabinose. Shown here is a representative example of FtsZ expressing cells labeled with 250 
µM 1 and 20 µM 2. Scale bar is 2 µm. 
 
 
Figure S18. Live-cell fluorescence imaging of uninduced cells. Representative live-cell 
imaging for control experiments. Cells that do not express the protein of interest, but that have 
been treated with 1 and 2, do not show distinct localization patterns. (scale bar = 1 µm). 
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Figure S19. In-gel fluorescence detection of proteins expressed from pQE80-L plasmids 
and labeled with 3. SDS–PAGE analysis of E. coli lysates. Protein expression was achieved by 
addition of 1 mM IPTG. Cultures were labeled with 3 when protein expression was induced. 
Cells were lysed and lysates were treated with 2. Western blot analysis against a C-terminal 
His5 tag with a primary antibody conjugated to Alexa Fluor 647 confirms protein expression.   
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Figure S20. In-gel fluorescence detection of proteins expressed from pBAD24 plasmids 
and labeled with 3. SDS–PAGE analysis of E. coli lysates. Protein expression was achieved by 
addition of 0.2% w/v L-arabinose (Ara). Cultures were labeled with 3 when protein expression 
was induced. Cells were lysed and lysates were treated with 2. Western blot analysis against a 
C-terminal myc tag with a primary antibody conjugated to Alexa Fluor 647 confirms protein 
expression. With hydrophilic fatty acid 3, we were unable to observe fluorescence labeling for 
the transmembrane protein, Tar. 
 
 
 
 
 
 
 
 
 
 
 
 
Ara
3
—
—
—
+
+
—
+
+
—
—
—
+
+
—
+
+
—
—
—
+
+
—
+
+
—
—
—
+
+
—
+
+
Tar CheA FtsZ FtsA
BODIPY
Coomassie
α–myc
188 KDa –
62 KDa –
49 KDa –
38 KDa –
28 KDa –
18 KDa –
14 KDa –
 – S36 – 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S21. Fluorescence emission of proteins expressed from pQE80-L plasmids and 
labeled with 3. Crude lysates from cells (labeled with 3) expressing one of the four bacterial 
proteins (Tar, CheA, FtsZ, or FtsA) were treated with 2 and separated using SDS–PAGE. 
Fluorescence measurements (from gels corresponding to Figure S19) were normalized to the 
bands corresponding to the labeled proteins in the coomassie gels. The extent of fluorescence 
enhancement above background measured by gel electrophoresis was 1.8-, 5.1-, 6.2-, and 4.3-
fold, respectively. Error bars denote standard deviations from three independent experiments. 
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Figure S22. Deconvoluted mass spectra of Tar. (A) Tar isolated from cells expressing both 
NMT and Tar but not labeled with 3. The mass at 61984 Da corresponds to unmodified Tar. (B) 
Tar isolated from cells labeled with 3. The mass at 62210 Da corresponds to Tar modified with 
3. Calculated and observed masses for modification of Tar are listed in Table S4. 
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Figure S23. Deconvoluted mass spectra of CheA. (A) CheA isolated from cells expressing 
both NMT and CheA but not labeled with 3. The mass at 73472 Da corresponds to the 
phosphorylated form of CheA. (B) CheA isolated from cells labeled with 3. The mass at 73639 
Da corresponds to CheA modified with 3 (sodium adduct). Calculated and observed masses for 
modification of CheA are listed in Table S5. 
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Figure S24. Deconvoluted mass spectra of FtsZ. (A) FtsZ isolated from cells expressing both 
NMT and FtsZ but not labeled with 3. The mass at 42365 Da corresponds to unmodified FtsZ, 
and the mass at 42575 Da corresponds to FtsZ modified from endogenous myristic acid. (B) 
FtsZ isolated from cells labeled with 3. The mass at 42590 Da corresponds to FtsZ modified 
with 3. Calculated and observed masses for modification of FtsZ are listed in Table S6. 
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Figure S25. Deconvoluted mass spectra of FtsA. (A) FtsA isolated from cells expressing both 
NMT and FtsA but not labeled with 3. The mass at 47583 Da corresponds to FtsA modified from 
endogenous myristic acid. (B) FtsA isolated from cells labeled with 3. The mass at 47596 Da 
corresponds to FtsA modified with 3. Calculated and observed masses for modification of FtsA 
are listed in Table S7. 
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Figure S26. The lipidome of cells treated with 3 does not differ from that of untreated 
cells. LC trace of intact lipids extracted from cells (A) untreated with azide fatty acids, or (B) 
treated with 3. The profile of (B) does not differ significantly from the LC trace of untreated cells 
in (A), suggesting that 3 is not incorporated into cellular lipids. 
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Figure S27. Representative live-cell images for chemotaxis and cell division proteins 
labeled with 2 and 3. (A) Structure of fatty acid analogue 3 used for live-cell labeling. (B) N-
terminal fluorescence labeling shows polar localization for Tar and CheA and septal localization 
for FtsZ and FtsA (scale bar = 1 µm). 
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